| Safety and feasibility of oral zinc for patients with GNAO1-related disorders (ZINCGNAO1) : an open-label, single-arm, single-centre, pilot trial in Germany | EClinicalMedicine |  | | 2026 | 2 | 0 |
|
| Pathogenic Gαo Mutants Drive Dominant GPCR Coupling in GNAO1 Encephalopathies | The FASEB journal | | | 2026 | 67 | 170 |
|
| Loss of the conserved switch III region in a G protein leads to severe pediatric encephalopathy | Science signaling |  | | 2025 | 29 | 0 |
|
| Clinical-molecular profiling of atypical GNAO1 patients : Novel pathogenic variants, unusual manifestations, and severe molecular dysfunction | Genes & diseases | | | 2025 | 50 | 50 |
|
| Atypical GNAO1 variants in severe childhood speech disorders: clinical, genetic, and molecular insights | Molecular autism | | | 2025 | 26 | 47 |
|
| Zinc for GNAO1 encephalopathy : preclinical profiling and a clinical case | Med | | | 2024 | 140 | 404 |
|
| Clinical and Molecular Profiling in GNAO1 Permits Phenotype–Genotype Correlation | Movement disorders | | | 2024 | 108 | 269 |
|
| GNAO1 Mutations Affecting the N‐Terminal α‐Helix of Gαo Lead to Parkinsonism | Movement disorders | | | 2024 | 124 | 322 |
|
| Personalized Drug Discoveries for Patients with GNAO1 Encephalopathies | | | | 2023 | 356 | 637 |
|
| Clinical Cases and the Molecular Profiling of a Novel Childhood Encephalopathy-Causing GNAO1 Mutation P170R | Cells | | | 2023 | 125 | 113 |
|
| In-depth molecular profiling of an intronic GNAO1 mutant as the basis for personalized high-throughput drug screening | Med | | | 2023 | 145 | 1 |
|
| Pediatric GNAO1 encephalopathies: from molecular etiology of the disease to drug discovery | Neural Regeneration Research | | | 2023 | 116 | 205 |
|
| Restoration of the GTPase activity and cellular interactions of Gαo mutants by Zn2+ in GNAO1 encephalopathy models | Science advances | | | 2022 | 217 | 217 |
|
| Unlocking the Wnt pathway : therapeutic potential of selective targeting FZD7 in cancer | Drug discovery today | | | 2021 | 555 | 560 |
|
